Identification of IOMA-class neutralizing antibodies targeting the CD4-binding site on the HIV-1 envelope glycoprotein.
van Schooten, J., Farokhi, E., Schorcht, A., van den Kerkhof, T.L.G.M., Gao, H., van der Woude, P., Burger, J.A., Meesters, T.G.R., Bijl, T., Ghalaiyini, R., Turner, H.L., Dorning, J., van Schaik, B.D.C., van Kampen, A.H.C., Labranche, C.C., Stanfield, R.L., Sok, D., Montefiori, D.C., Burton, D.R., Seaman, M.S., Ozorowski, G., Wilson, I.A., Sanders, R.W., Ward, A.B., van Gils, M.J.(2022) Nat Commun 13: 4515-4515
- PubMed: 35922441 
- DOI: https://doi.org/10.1038/s41467-022-32208-0
- Primary Citation of Related Structures:  
7U04, 7U0K, 7Z3A - PubMed Abstract: 
A major goal of current HIV-1 vaccine design efforts is to induce broadly neutralizing antibodies (bNAbs). The VH1-2-derived bNAb IOMA directed to the CD4-binding site of the HIV-1 envelope glycoprotein is of interest because, unlike the better-known VH1-2-derived VRC01-class bNAbs, it does not require a rare short light chain complementarity-determining region 3 (CDRL3) ...